Pharmacokinetically‐guided dosing to improve the efficacy of brigatinib in non‐small cell lung cancer patients

Brigatinib was recently approved for the treatment of anaplastic lymphoma kinase‐positive non‐small cell lung cancer and is dosed according to a one‐dose‐fits‐all paradigm. We aimed to identify a pharmacokinetically‐guided precision dosing strategy to improve treatment response with brigatinib throu...

Descripción completa

Detalles Bibliográficos
Autores principales: Koele, Simon E., van Beek, Stijn W., van der Wekken, Anthonie J., Piet, Berber, van den Heuvel, Michel M., ter Heine, Rob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292371/
https://www.ncbi.nlm.nih.gov/pubmed/34545619
http://dx.doi.org/10.1111/bcp.15088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292371/
https://www.ncbi.nlm.nih.gov/pubmed/34545619
http://dx.doi.org/10.1111/bcp.15088

Ejemplares similares